Development of an Osmotically Controlled Drug-Delivery System of Glipizide - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Development of an Osmotically Controlled Drug-Delivery System of Glipizide
The authors describe the development of an inclusion complex of GLZ and formulated an extended-release dosage form based on osmotic technology.


Pharmaceutical Technology
pp. 80-91

References

1. N.G. Das and S.K. Das, supplement to Pharm. Tech. 27 (6), 10–16 (2003).

2. F. Theeuwes, J. Pharm. Sci. Technol. 64 (12), 1987–1991 (1975).

3. R.W. Korsmeyer et al., Int. J. Pharm. 15 (1), 25–35 (1983).

4. H. Khurahashi, H. Kami, and H. Sunada, Chem. Pharm. Bull. 44 (4), 829–832 (1996).

5. B. Narasimhan, Adv. Drug Deliv. Rev. 48 (2–3), 195–210 (2001).

6. T. Durig and R. Fassihi, J. Control. Release 67 (1), 37–44 (2000).

7. S.M .Herbig, J.R. Cardinal, and RW. Korsmeyer, J. Control. Release 35 (2–3), 127–136 (1995).

8. Goodman and Gilman's The Pharmacological Basis of Therapeutics, J.G. Hardman, L.E. Limbird, and A.G. Gilman, Eds. (McGraw Hill, New York, 10th ed., 2001), p. 1927.

9. G. Amidon, H. Lennernas, and V.A. Shah, Pharm. Res. 12 (3), 413–420 (1995).

10. J. Dressman, J. Butler, and J. Hempenstall, Pharm. Technol. 25 (7), 68–76 (2001).

11. D. Horter and J. Dressman, Adv. Drug Deliv. Rev. 46 (1), 75–87 (2001).

12. C. Fernandes, M. Vieira, and F. Viega, Eur. J. Pharm. Sci. 15 (1), 79–88 (2002).

13. V.D. Mooter et al., Int. J. Pharm. 164 (1–2), 67–80 (1998).

14. K. Okimoto et al., J. Pharm. Res. 15 (10), 1562–1568 (1998).

15. K. Okimoto, R.A. Rajewski, and V.J. Stella, J. Control. Release 58 (1), 29–38 (1999).

16. C. Leuner and J. Dressman, Eur. J. Pharm. Biopharm. 50 (1), 47–60 (2000).

17. A. Avdeef, Adv. Drug Deliv. Rev. 59 (7), 568–590 (2007).

18. J.W. Moore and H.H. Flanner, Pharm. Technol. 20 (6), 64–74 (1996).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here